DURECT Corporation to Participate in the Berenberg NASH Day

Download PDF:

CUPERTINO, Calif., Feb. 21, 2019 /PRNewswire/ — DURECT Corporation (Nasdaq: DRRX) today announced that James E. Brown, President and CEO, and Mike Arenberg, Chief Financial Officer, will be participating in the Berenberg NASH Day, taking place Tuesday, February 26, 2019, at Berenberg’s New York City offices.  The format for the day includes an introductory session, a presentation by Dr. Raymond Chung of Harvard Medical School, a five minute presentation by DURECT management and other attending companies, and then one-on-one/small group meetings with companies and with key opinion leaders (Dr. Amon Asgharpour and Dr. Elliot Goodman of Mount Sinai, and Dr. Utpal Pajvani of Columbia University Medical Center).  Institutional investors and analysts that are attending the conference may request one-on-one meetings with DURECT management through the conference coordinators.

About DURECT Corporation
DURECT is a biopharmaceutical company actively developing therapeutics based on its Epigenetic Regulator Program and proprietary drug delivery platforms.  DUR‑928, a new chemical entity in Phase 2 development, is the lead candidate in DURECT’s Epigenetic Regulator Program.  An endogenous, orally bioavailable small molecule, DUR-928 has been shown in preclinical studies to play an important regulatory role in lipid homeostasis, inflammation, and cell survival.  Human applications may include chronic liver diseases such as nonalcoholic steatohepatitis (NASH), acute organ injury such as Alcoholic Hepatitis (AH) and acute kidney injury (AKI), and inflammatory skin conditions such as psoriasis and atopic dermatitis.  DURECT’s advanced oral and injectable delivery technologies are designed to enable new indications and enhanced attributes for small-molecule and biologic drugs.  Late stage product candidates in this category include POSIMIR® (bupivacaine extended-release solution), an investigational locally-acting, non-opioid analgesic intended to provide up to 3 days of continuous pain relief after surgery, and ORADUR®-Methylphenidate ER Capsules, approved in Taiwan as Methydur Sustained Release Capsules, where it is indicated for the treatment of attention deficit hyperactivity disorder (ADHD).  In addition, for the assignment of certain patent rights, DURECT will receive single digit sales-based earn-out payments from U.S. net sales of Indivior’s PERSERIS (risperidone) drug for schizophrenia, which was approved in July 2018.  For more information, please visit www.www.durect.com.

NOTE: ORADUR®, POSIMIR® and SABER® are trademarks of DURECT Corporation. Other referenced trademarks belong to their respective owners. DUR-928 and POSIMIR are drug candidates under development and have not been approved for commercialization by the U.S. Food and Drug Administration or other health authorities.

DURECT Forward-Looking Statement

The statements in this press release regarding the potential benefits and uses of drug candidates, including the potential earn-out payments receivable from Indivior, as well as the potential use of POSIMIR to treat post-surgical pain, and the potential use of DUR-928 to treat Alcoholic Hepatitis, hepatic and renal diseases such as nonalcoholic steatohepatitis (NASH) and Primary Sclerosing Cholangitis (PSC), and inflammatory skin conditions such as psoriasis and atopic dermatitis are forward-looking statements involving risks and uncertainties that can cause actual results to differ materially from those in such forward-looking statements. Potential risks and uncertainties include, but are not limited to, the risks that PERSERIS will not obtain market acceptance and meaningful sales, as well as possible adverse events associated with the use of PERSERIS, POSIMIR and DUR-928, delays and costs due to additional work or other requirements imposed by regulatory agencies for continued development, approval or sale of POSIMIR and DUR-928, and the possibility that studies of DUR-928 will not replicate results from earlier preclinical or clinical trials.  Further information regarding risks related to DUR-928 and POSIMIR and other risks related to DURECT is included in DURECT’s Form 10-Q filed on November 5, 2018 under the heading “Risk Factors.”


Cision View original content:http://www.prnewswire.com/news-releases/durect-corporation-to-participate-in-the-berenberg-nash-day-300799047.html


Michael H. Arenberg, Chief Financial Officer, DURECT Corporation, (408) 346-1052, mike.arenberg@durect.com, or Ashley R. Robinson, LifeSci Advisors, LLC, (617) 535-7742, arr@lifesciadvisors.com

Scroll to Top